Results 171 to 180 of about 31,387 (227)

Sex Differences in Cancer Immunotherapy—Clinical Evidence and Mechanisms With a Focus on NSCLC

Immunological Reviews, Volume 338, Issue 1, March 2026.
ABSTRACT Accumulating evidence suggests that the immune system shows subtle but relevant differences between men and women. These differences may have an impact on cancer development and TME composition as well as responses to and adverse events elicited by immunotherapies.
Eva Krieghoff‐Henning, Balagopal Pai, Maike Collienne, Isabel Ben‐Batalla, Sonja Loges   +4 more
wiley   +1 more source

Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and <i>FGFR</i> Alterations: Final Results From the Phase II NORSE Study. [PDF]

J Clin Oncol
Loriot Y, Powles T, Moreno V, Kang TW, Cicin I, Girvin A, Akapame S, O'Hagan A, Zhu W, Tammaro M, Thomas S, Triantos S, Siefker-Radtke AO.   +12 more
europepmc   +1 more source

Dysregulated Peroxiredoxins in Bladder Cancer Are Associated With an Altered Tumour Immune Microenvironment

Journal of Cellular and Molecular Medicine, Volume 30, Issue 5, March 2026.
ABSTRACT Peroxiredoxins (PRDXs) are antioxidant enzymes that scavenge hydrogen peroxide and protect cells from reactive oxygen species (ROS). There are six genes encode different types of PRDXs (PRDX1–PRDX6) in humans and most of them are overexpressed in tumours; however, their expression patterns and prognostic value in bladder cancer (BLCA) remain ...
Jarett Wallerson, Sara Rostampour, Shaolei Teng, Dawit Kidane   +3 more
wiley   +1 more source

Metastatic Urothelial Carcinoma Presenting as Rectal Linitis Plastica: A Rare Case Report. [PDF]

Gastro Hep Adv
Lee C, Awad N, Kostalas S.
europepmc   +1 more source

Micropapillary urothelial carcinoma metastatic to the male breast

The Breast Journal, 2019
Simon F. Roy, Marie‐Christine Guilbert
openaire   +2 more sources

The Influence of Extracellular Citrate in Physiological Concentration on the Proliferation of Malignant Melanoma

Journal of Cellular and Molecular Medicine, Volume 30, Issue 5, March 2026.
ABSTRACT Cancer cells rely on citrate for multiple metabolic processes, suggesting that limiting the availability of extracellular citrate may represent a novel therapeutic strategy. The plasma membrane citrate transporter (pmCiC) has been implicated in the pathogenesis of several cancers before, and its activity can be inhibited by gluconate.
Konstantin Drexler, Barbara Schwertner, Veronika Zenderowski, Laura Schreieder, Dennis Christoph Harrer, Mark Berneburg, Edward Geissler, Maria Mycielska, Sebastian Haferkamp   +8 more
wiley   +1 more source

Clonal diversity shapes the tumour microenvironment leading to distinct immunotherapy responses in metastatic urothelial carcinoma. [PDF]

Nat Commun
Kamatani T, Umeda K, Iwasawa T, Miya F, Matsumoto K, Mikami S, Hara K, Shimoda M, Suzuki Y, Nishino J, Kato M, Kakimi K, Tanaka N, Oya M, Tsunoda T.   +14 more
europepmc   +1 more source

Harnessing blue light photobiomodulation for cancer therapy: Evidence from a systematic review

Photochemistry and Photobiology, Volume 102, Issue 2, Page 370-399, March/April 2026.
Conventional treatments for various types of cancer are often associated with tumor recurrence and aggressiveness. Photobiomodulation with blue light (BL; 450–470 nm) emerges as a promising alternative with antitumor effects. This systematic review, with 37 in vitro and in vivo studies from 2002 to 2024, revealed that BL reduces cell viability ...
Bárbara Evelyn Santos de Lima, Rebeca Barros Nascimento, Ana Paula Mariano Santos Ginez, Maria Stella Moreira, Rebeca Boltes Cecatto, Rodrigo Labat Marcos, Maria Fernanda Setúbal Destro Rodrigues   +6 more
wiley   +1 more source

SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma. [PDF]

Future Oncol
Powles TB, Grande E, Alimohamed N, Oliveira N, Sridhar SS, Drakaki A, Kanesvaran R, Loriot Y, Necchi A, Franco S, Jiang D, Apolinario K, Zhang W, Galsky MD.   +13 more
europepmc   +1 more source

Serum Symmetric Dimethylarginine as a Predictor of Toxicity of Carboplatin in Dogs

Veterinary and Comparative Oncology, Volume 24, Issue 1, Page 140-149, March 2026.
ABSTRACT Glomerular filtration rate (GFR) predicts carboplatin clearance and myelotoxicity in humans and cats. This relationship is unknown in dogs. In canines, elevated serum symmetric dimethylarginine (SDMA) correlates with reduced GFR. This study prospectively evaluated whether dogs with elevated SDMA (> 14 μg/dL) are at increased risk of ...
Alexandra Gareau, Mark G. Papich, Brolin J. Evans, Joanne L. Intile   +3 more
wiley   +1 more source